Grail, Inc. (GRAL) Chief Executive Officer Robert P. Ragusa recorded $409,245 in stock sales, according to a Form 4 filed with the Securities and Exchange Commission. The transactions, all designated with transaction code "S," were executed in multiple tranches at prices between $46.73 and $53.01.
Per the filing, Ragusa sold 980 shares of common stock on March 5, 2026, at $53.01 each. On March 9, 2026, he sold two additional lots: 7,203 shares at $47.93 and 258 shares at $46.73. After these dispositions, Ragusa directly holds 642,084 shares of Grail.
The Form 4 notes that the sales were carried out to satisfy withholding tax obligations related to award vesting and the delivery of shares. The filing does not indicate any other motives for the transactions.
At the time these transactions were reported, Grail shares were trading at $49.82. That price point reflects a 42% decline year-to-date, despite a 55% increase in the stock over the past 12 months.
Separately, Grail recently released its fourth-quarter and full-year 2025 results, which the company said were in line with its prior preannouncement. The company's Galleri multi-cancer early detection test demonstrated 35% year-over-year growth in testing volume, a result that exceeded Canaccord Genuity's estimates and the FactSet consensus.
However, the NHS-Galleri trial did not meet its primary endpoint of reducing diagnoses of Stage III-IV cancers, a development that has altered analysts' assessments of Grail's near-term clinical outlook. In response to the trial outcome and the reported results, Canaccord Genuity reduced its price target on Grail from $105 to $80 while retaining a Buy rating. TD Cowen reiterated a Hold rating with a $114 price target and highlighted the potential of the Galleri test. Baird initiated coverage with an Outperform rating and a $113 price target, noting that Grail's prospects remain speculative.
The combination of executive stock sales to cover tax liabilities, mixed clinical readouts, and divergent analyst reactions creates a complex picture for investors assessing Grail's trajectory. The filings and corporate results presented in public disclosures provide the factual basis for the transactions and the market responses described here.